| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Deschatelets Pascal | Chief Scientific Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM | /s/ David Watson, attorney-in-fact for Pascal Deschatelets | 23 Jan 2026 | 0001657720 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLS | Common Stock | Sale | $129,025 | -5,928 | -0.51% | $21.77 | 1,151,382 | 22 Jan 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2026. |